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ABSTRACT  
 
Pluripotency defines the ability of stem cells to differentiate into all the 
lineages of the three germ layers and self-renew indefinitely.  Somatic cells 
can regain the developmental potential of embryonic stem cells following 
ectopic expression of a set of transcription factors or, in certain 
circumstances, via modulation of culture conditions and supplementation with 
small molecule, i.e. induced pluripotent stem (iPS) cells.  Here, we discuss the 
use of fetal tissues for reprogramming, focusing in particular on stem cells 
derived from human amniotic fluid, and the development of chemical 
reprogramming.  We next address the advantages and disadvantages of 
deriving pluripotent cells from fetal tissues and the potential clinical 
applications.  
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A. Rejuvenating somatic cells to pluripotency. 
 
Fetal cell fate is reversible chemically.  We previously reprogrammed human 
fetal stem cells to functional pluripotency using valproic acid (VPA) and 
without genetic manipulation or ectopic expression of pluripotency factors (1-
3).  Somatic cells can be reprogrammed into pluripotent stem cells, i.e. 
induced pluripotent stem (iPS) cells, to regain the developmental potential of 
embryonic stem (ES) cells, including the capacity to self-renew indefinitely 
and to differentiate into all the lineages of the three germ layers.  Rejuvenated 
cells are attractive tools in biomedical research to study development and 
disease, and in regenerative medicine to produce patient-specific cells that 
can be injected without immunosuppressant.  Pioneered by Yamanaka’s 
group in 2006-7, iPS cells were first generated by retroviral transduction of a 
combination of four transcription factors, i.e.OCT4, KLF4, SOX2 with or 
without c-MYC (4-6) or OCT4, SOX2, NANOG with or without LIN28 (5, 6).  
Various reprogramming strategies have since been developed to increase 
reprogramming efficiency and create iPS cells free of exogenous DNA 
(footprint-free) with the purpose of avoiding tumorigenic insertional mutations 
and reactivation of transgene expression during differentiation, which 
represent a major hurdle for iPS cells applications.  Integration-free 
techniques use for example minicircle DNA, transposons, RNA viral vectors, 
acid-free methods, and episomal vectors, with episomal reprogramming being 
at present the most efficient method and the most likely translatable 
technology for producing clinical-grade human iPS cells via ectopic 
expression of transcription factors (7).  Manipulation of the environment, such 
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as biophysical cues, can also modulate cell fate (8). Similarly, chemicals, in 
particular small molecules, have been used to modulate reprogramming, 
either by increasing reprogramming efficiency, and/or to replace one or more 
transcription factors (9). Several small molecule compounds involved in 
epigenetic regulation have been identified for their role in the reprogramming 
process either via somatic cell nuclear transfer (SCNT), or ectopic expression 
of a define set of transcription factors to replace one, or more, of the 
reprogramming factors.  For example, it was shown that hyperacetylation 
improves reprogramming of somatic nuclei following nuclear transfer (10) and 
that the histone deacetylase inhibitor trichostatin A (TSA) reduces abnormal 
DNA hypermethylation following cloning by SCNT, thereby increasing success 
rate of mouse cloning via SCNT (11).  Similarly, the histone deacetylase 
inhibitor valproic acid improves reprogramming efficiency of mouse embryonic 
fibroblasts (MEF) without the introduction of c-Myc (12) and enables the 
reprogramming of primary human fibroblasts with only two factors, Oct4 and 
Sox2, without the need for the oncogenes c-Myc or Klf4 (13, 14).  Generally 
used for the treatment of epilepsy and bipolar disorder, VPA (2-propyl 
pentanoic acid) enhances OCT4 promoter activity via activation of the 
PI3K/Akt/mTOR pathway in mouse cells (15, 16).  VPA is involved in several 
regulatory mechanisms including GSK3b, Akt, ERK, phosphoinositol, 
tricarboxylic acidcycle, GABA, and OXPHOS pathways (17).  
 
Induced pluripotent stem cells, which can be generated from different tissues, 
have properties that differ according to their tissue of origin, because they 
maintain a unique residual DNA methylation that influences their 
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differentiation potential, i.e. “epigenetic memory of the donor tissue” (18).  In 
addition, the tissue of origin can also influence the efficiency and yield of 
reprogramming.  For example, keratinocytes being reprogrammed more 
readily than fibroblasts (19, 20), and fibroblasts isolated from different tissues 
vary in their reprogramming efficiency.  In that context, stem cells, which are 
less lineage committed than terminally differentiated somatic cells, are easier 
to reprogram, and can be reprogrammed with a reduced number of factors, 
and adult neural stem cells can revert to functional pluripotency using OCT4 
only (21).  In addition to the differentiation status of the tissue of origin, the 
development age of the parental population also influences the capacity of the 
cells to revert to an earlier state of pluripotency.  For example, embryonic and 
fetal tissues can be reprogrammed with a higher efficiency than adult tissues, 
yielding iPS cells that are functionally most comparable to embryonic stem 
cells (18, 22, 23).  Of importance, the Ink4/Arf locus, which encodes 
p15(INK4b) , ARF, and p16(INK4a) genes in human chromosome 9p21, has 
been shown to be a barrier for iPS cell derivation, with the locus being 
silenced in both murine and human iPS and ES cells (22).  The expression 
level of the Ink4/Arf locus, which is progressively upregulated in older cells 
and in cells from late developmental stages, inversely parallels 
reprogramming efficiency, explaining why older cells are more difficult to 
reprogram.  Indeed, embryonic and fetal tissues can be rejuvenated using a 
reduced number of transcription factors.  For example, human neural stem 
cells (NSCs), CD34+ amniotic fluid cells, and keratinocytes, as well as mouse 
fibroblasts have been reprogrammed with only OCT4, either alone (24, 25), or 
in conjunction with a small molecule cocktail (26, 27).  Small molecules are 
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advantageous because they are not expensive, non-immunogenic, cell-
permeable, easily synthesized, and target specific pathways.  Complete 
chemical reprogramming in the absence of genetic manipulation has been 
overcome in mouse epiblast stem cells, which already express pluripotency 
markers oct4, sox2 and nanog but are incapable to contribute to chimerism, 
using a combination of small molecules to simultaneously inhibit LSD1, ALK5, 
MEK, FGFR and GSK3 (28).  More recently, mouse embryonic fibroblasts 
have been fully reprogrammed to pluripotency using only small molecule 
compounds (29). 
 
 
B. Fetal tissues as a source for reprogramming 
 
Mesenchymal stem cells (MSCs), originally isolated from the bone marrow but 
found in various prenatal and postnatal tissues at different stages of 
development, are plastic-adherent cells with clonogenic capacity 
characterized by the co-expression of CD73, CD105 and CD90, absence of 
expression of hematopoietic markers as well as pluripotency markers, their 
ability to differentiate in vitro to adipogenic, chondrogenic, and osteogenic 
cells.  MSCs do not form teratomas following subcutaneous injection in 
immune-compromised mice.  This definition complies with the minimal criteria 
for defining multipotent MSCs according to the International Society for 
Cellular Therapy position statement (30).  MSCs have generated substantial 
interest for use in cell therapy and tissue engineering due to their ability to 
migrate to sites of injury and regenerate and repair damaged tissues (31, 32).  
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Functionally, MSCs are metabolically active, producing cytokines and growth 
factors.  They have immunosuppressive properties, suppressing T cell 
proliferation and dendritic cell maturation, reducing B cell activation, and 
polarizing macrophages from a M1 pro-inflammatory to a M2 anti-
inflammatory type in response to acute injury and/or inflammation (33).  Fetal 
MSCs can be isolated from fetal tissues, such as liver, bone marrow, and 1st 
trimester blood (34, 35), as well as amniotic fluid (36, 37) and placenta (38).  
We, and others, have shown that MSCs isolated from fetal tissues show 
advantageous characteristics compared to their adult counterparts, including 
smaller size, active telomerase with longer telomeres, faster kinetics and 
greater expansion capacity, but do not self-renew indefinitely.  They also 
show a unique adhesion molecule profile and broader differentiation potential, 
although they are not pluripotent, i.e. have the capacity to differentiate into all 
the lineages of the three germ layers.  For example, human fetal blood MSCs 
and first trimester chorionic stem cells (CSC) transplanted perinatally in a 
mouse model of osteogenesis imperfecta reduced considerably long bone 
fracture rates and bone brittleness, and increased bone volume, with donor 
cells engrafting at sites of bone formation and differentiating into functional 
osteoblasts, producing the Collagen Type 1 alpha 2 chain which is absent in 
non-transplanted mice (39-41).  Similarly to other fetal MSCs, human c-Kit+ 
amniotic fluid stem cells (AFS cells) show broader differentiation capacity, co-
expressing CD73, CD90 and CD105 but not hemoatopoietic markers or 
pluripotency markers (37).  We demonstrated there that despite sharing 
91.6% RNA transcriptome identity with human embryonic stem cells, human 
first and second trimester AFS cells do not express most markers of 
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pluripotency and are not pluripotent, failing to form teratomas in vivo, although 
they show evidence of lineage priming.  However, along with placental 
chorionic MSCs (CSCs), AFS cells are abundant, readily available and easily 
accessible, being collected at mid-gestation using minimally invasive 
technique during prenatal diagnosis or fetal treatments.  Similar to other fetal 
stem cells, AFS cells have a small size, high growth kinetics, possess an 
active telomerase, and a more primitive phenotype.  They also provides the 
opportunity to generate “younger” pluripotent cells, i.e. with reduced number 
of acquired mutations and longer telomeres, providing unprecedented 
opportunity to derive patient-specific iPS cells for prenatal and perinatal use, 
whilst avoiding the risk of immunorejection and the need of 
immunosuppressant.  Because they are isolated from fetal tissues, fetal 
MSCs may have accumulated less genetic damage or somatic mutations than 
older cell types. 
 
Deriving iPS cells from peripheral blood (PB) is convenient and less invasive 
than from dermal fibroblasts, where several weeks are required to establish a 
primary cell culture from skin biopsy.  Fetal HSCs can also be derived at birth 
from the umbilical cord blood (UCB).  Around 1% of the cells isolated from 
UCB expresses the CD34 surface marker, and are negative for CD38.  The 
frequency of CD34+ cells in cord blood is higher than that of adult BM or 
peripheral blood following cytokine mobilization (42), and compared with BM 
cells, CD34+ UCB cells proliferate more rapidly and generate larger numbers 
of progeny cells (43).  Besides, it was demonstrated that cord blood HSCs 
express neuronal proteins and can differentiate into neuronal-like cells or glial 
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cells (44).  Induced pluripotent stem cells derived from human cord blood have 
recently been shown to generate a large number of functional neurons 
including dopaminergic cells, which may serve for the development of novel 
regenerative treatment strategies (45).  
 
 
C. Chemical reprogramming of human fetal stem cells isolated from first 
and second trimester amniotic fluid 
 
We previously used microarray-based transcriptome analysis to investigate 
whether first and second trimester AFSC show similar gene expression 
profiles and reported that both populations are related but differ with regards 
to cell size and molecular signature, with a cell-specific gene expression 
signature comprising 366 genes for first trimester and 340 genes for second 
trimester AFSC (37).  Residual levels of OCT4 can be deteced in both first 
and second trimester AFS cells, whilst SOX2 is only expressed in first 
trimester AFS cells, when the cells are expanded on plastic at 37 1C with 5% 
CO2 atmosphere, either in alpha minimum essential medium (a-MEM) 
containing 15% fetal bovine serum (FBS), 1% glutamine and 1% 
penicillin/streptomycin supplemented with 18% Chang B and 2% Chang C 
(36); in Dulbecco’s Modified Eagle’s Medium high-glucose (DMEM) containing 
10% FBS supplemented with 2 mmol/l L-glutamine, 50 IU/ml penicillin, 50 
mg/ml streptomycin (1, 3).  However, expression levels are relatively low 
compared to those found in ES cells, i.e. <1% for OCT4 and <10% for SOX2, 
albeit expression is homogeneous, as shown by confocal microscopy and flow 
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cytometry.  We hypothesized that low expression levels of OCT4 and SOX2 
might reflect the susceptibility of the cells to revert to an earlier state of 
pluripotency under appropriate culture conditions and without the need of 
exogenous expression of transcription factors.  We found that culturing the 
cells on conditions designed to sustain the pluripotent phenotype of hES and 
iPS cells, i.e. culture on Matrigel-coated plastic plates in low growth factor 
hES cells feeder-free culture medium, increased levels of expression of OCT4 
and SOX2, and that supplementation of the culture with 1 mM VPA for 5 days, 
followed by culture on Matrigel in iPS cell medium fully reverted the cells to 
functional pluripotency at a clonal level, as evidenced by their capacity to form 
embryoid bodies in vitro and teratomas in vivo, both containing cells 
expressing markers of the three germ layers, such as neural tube and 
squamous epithelium (ectoderm), collagenous tissue and blood vessels of 
human origin (mesoderm), and alveolar and gut epithelium (endoderm).  
Reprogrammed cells homogeneously co-express Tra-1-60, DNMT3b and 
REX1, which satisfies the stringent criteria for human fully-pluripotent cells 
(46).  Human iPS cells derived from both first and second trimester AFS cells 
expanded over 8 weeks following reprogramming maintain genetic stability, 
protein-level expression of key pluripotency factors, high cell-division kinetics 
(21  3.4 h population doubling), active telomerase activity, and capacity to 
differentiate into lineages of the three germ layers, such as definitive 
endoderm, hepatocytes, bone, fat, cartilage, neurons and oligodendrocytes.  
Some cells organized in embryoid body structures were observed contracting 
rhythmically in synchrony, mimicking a primitive cardio sphere appearance.  
VPA-induced iPS cells showed repression of X-inactivation (as seen by 
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absence of expression of the X-linked Xist gene), with expression of a subset 
of X-linked genes in the gene arrays showing that CXORF15, PLS3, RBBP7, 
and UTX being expressed, confirming repression of X-chromosome 
inactivation in AFS-CiPS cells.  Of interest, although the transcriptome profile 
of chemically reprogrammed AFS cells clearly separate from those of their 
parental lines, with an overlap between AFS-CiPS cells and hES cells of 7572 
genes, among which 273 genes associated with WNT and NOTCH signaling 
pathways were only expressed in iPS and hES cells but not in the parental 
population, AFS-CiPS cells are not identical to hES cells, with 15% of hES 
cells genes not being expressed in CiPS cells (1).  However, similarly to hES 
cells but contrary to the parental line, AFS-iPS cells express tripartite motif 
protein 28 (TRIM28), also known as Transcription Intermediary Factor–1 
beta(TIF1b) or KRAB-Associated Protein 1 (KAP1), which is a specific and 
indispensable factor for the maintenance of pluripotency in hES cells (47).  
Interestingly, we showed that second trimester AFS cells, which do not 
express SOX2, can be efficiently reprogrammed using a similar protocol (3), 
albeit abolishing OCT4 expression in both first and second trimester AFS cells 
prevented VPA-mediated reprogramming, as seen by the absence of Tra-1-
60+ cells (personal communication, unpublished data).  These results indicate 
that OCT4, but not SOX2, is indispensable for the chemical reprogramming of 
human somatic cells using VPA.  The residual expression of OCT4 in amniotic 
fluid stem cells raised the possibility that AFS cells might originate from a 
founder population of stem cells of epiblast origin such as primordial germ 
cells, which may have been retained in the amniotic fluid early during their 
migration to the genital ridges.  The epiblast origin of AFS cells was further 
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documented during whole genome transcriptome analysis by high expression 
of FGF5, a marker of pluripotent epiblast cells which is not expressed in the 
inner cell mass (ICM).  The transcriptome of AFS-iPS cells showed absence 
of expression of markers which constitute the NCSC molecular signature, 
such as FOXD3 and RET, indicating that AFSC might be of primordial germ 
cells/progenitors origin (1).  Interestingly, we showed that AFS cells express 
the PGC markers c-KIT, T, FGF8, SOX17, STELLA, DAZL, NANOS2, 
NANOS3, VASA, SSEA1, FRAGILIS and PUM2 but not ERAS, which is 
repressed in PGC (48). At the protein level, the AFS cell population contains 
cells positive for FRAGILIS, SSEA1, TNAP, NANOS, BLIMP1, PUM2, 
STELLA, DAZL and VASA. Interestingly, SSEA1, which is expressed in 
human PGC but not in hES cells, is expressed in AFS cells. Tissue Non-
Specific alkaline Phosphatase (TNAP) is strongly expressed in the cytoplasm; 
as well as BLIMP1, a transcriptional repressor expressed in the nucleus of 
PGC which progressively relocates to the cytoplasm during migration of PGC 
to the genital ridge but is absent in EG cells (49); with FRAGILIS and STELLA 
being expressed in both nucleus and cytoplasm of AFS cells, as is the case 
for PGCs (50). NANOS and DAZL, known to relocate from the nucleus to the 
cytoplasm in human fetal germ cells and PUM2 (51), are expressed in the 
cytoplasm of AFS cells.  In migratory PGC, this relocation with parallel down-
regulation of OCT4 and the onset of expression of VASA, which in AFSC is 
expressed in the cytoplasm, indicating that AFSC might be related to PGC, 
which have been retained in the amniotic fluid early at the start of their 
migration to the genital ridge.  
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D. Advantages and disadvantages of deriving iPS cells from fetal tissues 
 
Cells isolated from fetal tissues can be used for both prenatal and perinatal 
autologous and allogeneic therapy.  However, the isolation of fetal cells from 
fetal somatic tissues in the first trimester requires pregnancy termination, an 
obstacle to autologous applications.  The harvest of fetal blood in continuing 
pregnancies is feasible, but technically challenging.  One group has 
developed ultrasound-guided fetal blood sampling in ongoing pregnancies at 
risk of haemoglobinopathies with a loss rate of only 5% at gestations as early 
as 12 weeks (52).  Thin-gauge embryo-fetoscopes also allow early fetal blood 
sampling from the umbilical cord under direct visualization (53).  Alternatively, 
amniotic fluid stem cells can be isolated during ongoing pregnancy from the 
surplus of amniocentesis, but this is not a prenatal diagnostic systematically 
performed. Most suitable fetal tissues include term placenta, which is 
discarded at birth and can be stored to isolate stem cells.  We, and others, 
have shown that term placenta contains chorionic stem cells (CSC) with a 
similar phenotype to AFS cells (38).   
 
Relevant to cell therapy, MSCs isolated from fetal tissues are more 
advantageous than their adult counterparts, including their more primitive 
phenotype, unique adhesion molecule profile, active telomerase, and smaller 
size.  The multi-organs engraftment and therapeutic potential of human first 
trimester MSCs following prenatal and neonatal cell therapy has been 
documented in a number of animal models of human pathology, as well as in 
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humans (54).  Of concern, there are several key hurdles that limit their 
translational potential: (a) the rarity of the cells and heterogeneity of the 
population, which necessitates in vitro cell expansion, (b) their isolation 
requires invasive procedures (c) they undergo replicative senescence, limiting 
the yield of primary cells that can be expanded in vitro, and (d) the rapid 
decrease in differentiation potential during passaging of primary cells.  These 
changes in phenotype following in vitro culture hinder the development of 
effective therapies for long-term treatment, and highlight the need for new cell 
sources of MSCs for clinical applications.  It is now possible to produce high 
yields of MSCs from pluripotent stem cells, replacing the need to use primary 
MSCs isolated from fetal tissues.  The rationale behind replacing primary 
MSCs by MSCs derived from iPS cells is that in vitro cell expansion is not 
performed on primary MSCs but on self-renewing pluripotent stem cells, to 
bypass replicative senescence (55).  Deriving MSCs from fetal iPS cells 
produced from amniotic fluid or placenta during ongoing pregnancy offers the 
possibility to generate cells with a fetal, as opposed to adult, MSC phenotype 
from non-aborted tissues. 
 
Recent studies indicate that MSCs produced from iPS cells have some 
advantages over primary MSCs.  For example, Lian et al (56) induced human 
iPS cells to MSC differentiation with a clinically compliant protocol and 
showed the resulting MSCs attenuated severe hind-limb ischemia and 
promoted vascular and muscle regeneration following transplantation into 
mice, with the benefits of iPS-MSCs on limb ischemia being superior to those 
of primary adult bone marrow MSCs.  The authors postulate that the greater 
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potential of iPS-MSCs may be attributable to their superior survival and 
engraftment after transplantations.  Importantly, MSCs derived from 
pluripotent cells (ES) also display immunomodulatory properties, displaying a 
unique immunophenotypic properties, with a smaller size and >30,000 fold 
proliferative capacity than bone marrow-derived MSCs (57).   
 
 
E. iPS cells derived from fetal tissues for clinical applications 
 
Generating iPS cells for clinical application aims at avoiding the potential risk 
of insertional mutagenesis associated with the random integration of the 
transgenes within the genome.  Attempts to overcome this led to the 
development of excisable vectors, using Cre-recombinase to remove the 
integrated construct after reprogramming. However, each excision event 
leaves a small long terminal repeat fragment behind, which can still cause 
genotoxicity (58-60).  An alternative is the piggyBac transposon system, 
where the transposase can be used after reprogramming to completely 
remove the transposon (61, 62). Nevertheless, the efficiency of this system is 
low, and DNA sequencing is required to screen for any genetic modifications 
at the insertion sites, making this technology too laborious to be used in a 
clinical setting.  Non-integrating systems were developed to overcome the 
pitfall of insertional mutagenesis and produce safer, clinically relevant iPS 
cells.  These include both virus-based and virus-free approaches.  Non-
integrating viral methods utilize adenovirus- or Sendai virus-based systems to 
transfect plasmids carrying the transgenes of interest (63).  However, these 
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methods are hindered by even lower efficiency levels of around 0.001%, due 
to transient expression of the transgenes.  Subsequently, another method 
used to achieve non-integrative transgene expression used episomal 
constructs (64) or mini-circle vectors (65, 66).  Both are replicated once at 
every cell cycle under drug selection conditions, but once reprogramming is 
completed and drug selection is withdrawn the episomes are gradually lost, 
leading to transgene-free iPS cells.  Despite this clear advantage, this method 
requires the use of the oncoprotein SV40LT which, combined with low 
efficiency, makes the protocol unsuitable to clinical use, particularly due to the 
laborious and time-consuming analysis required ensuring that the generated 
iPS cells are free of vector-derived sequences.  A safer approach is the use of 
RNA-based technology (28), albeit efficiency remains low, and the technique 
is difficult to reproduce (for a complete review refer to (67).  Chemical 
reprogramming using small molecules offers unprecedented tools to produce 
footprint-free pluripotent cells without the use of exogenous transgene.  In 
addition, small molecules used for reprogramming are cell permeable, non-
immunogenic, easily synthesized and screened, protocols better 
standardized, and their effects on inhibiting and activating specific pathways 
are often reversible and can be finely adjusted (29). 
 
Cell therapy aims at replacing damaged cells by healthy ones to restore 
function of organs and tissues, stimulating endogenous cells to promote 
tissue repair, or producing growth factors to stimulate the maturation of 
endogenous progenitors.  Alternatively, donor cells can modulate the 
endogenous immune system to induce tolerance.  The number of donor cells 
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available and the instability of the cellular phenotype during ex vivo expansion 
greatly limit the treatment of genetic diseases or pathologies, with prenatal 
and neonatal onset.  Generating and banking pluripotent stem cells from fetal 
tissues can pave the way to use young rejuvenated cells to treat the fetus and 
prevent organ injury before irreversible damage in a fetal-to-fetal approach 
using cells from a similar developmental stage.  There is the necessity to 
establish a GMP (Good Manufacturing Practice) compliant collection of 
human fetal stem cells for therapeutic grade banking (68).  Although 
experimental research is at present at a preliminary preclinical stage and that 
proof of concept in larger animal models might be necessary before entering 
clinical trials; our strategy consists in developing GMP compliant cells during 
the lifetime of experimental research to allow rapid transition from bench to 
bedside when experimental data will support applications for clinical trials 
(69). 
 
Because pluripotent stem cells form teratomas in vivo, they must be 
differentiated into specific lineages of interest in vitro and selected for 
absence of pluripotency marker expression (for example by absence of CD24 
expression using flow cytometry cell sorting) prior to being injected.  However, 
the capacity of iPS cells to differentiate is regulated by the Germ Cell Nuclear 
Factor (GCNF) (Nuclear receptor subfamily 6 group A member 1, NR6a1), a 
silencer of pluripotency genes required for the repression of pluripotency 
genes during development and used as a marker to distinguish completely 
reprogrammed iPS cells from incompletely pluripotent cells (70). Therefore, 
one of the challenges of using iPS cells for cell therapy is the ability to 
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completely repress the pluripotency network upon differentiation.  For 
example, if OCT4 expression is maintained after differentiation, this leads to 
poor differentiation and aberrant expression of differentiated genes.  In 
addition, the capacity of iPS cells to differentiate into specific lineage greatly 
depends on the tissue of origin, because of the epigenetic memory of the 
cells, which retain a propensity to differentiate into lineages of the parental cell 
population. While certain protocols are robust and well established, a number 
of them remain long and challenging.  
 
 
Summary  
 
Generation of induced pluripotent stem (iPS) cells can be achieved from 
various fetal and adult somatic cells and stem cells using different systems for 
the delivery of ectopic transcription factors, or by manipulation of the culture 
conditions and supplementation of the culture medium with small molecules to 
specifically inhibit or activate pathways involved in the establishment and 
maintenance of pluripotency.  Whilst iPS cells can be generated from different 
tissues, the derivation of pluripotent stem cells from fetal tissues, in particular 
amniotic fluid, has important potential to treat a number of genetic disease or 
acute pathologies before birth or during the neonatal period.  In addition, a 
chemical approach to reprogramming fetal tissues in mouse and humans 
allows the derivation of pluripotent cells free from exogenous DNA, without 
the risk of re-activation of reprogramming factors.  Fetal stem cells have a 
lower incidence of genomic mutations, longer telomeres and active 
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telomerase, thereby producing younger iPS cells upon reprogramming.  
However, fetal tissues are not easy to isolate during ongoing pregnancy, with 
the exception of amniotic fluid, which is routinely sampled at mid-gestation for 
prenatal diagnostic.   
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